These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 31892339)

  • 21. Prognostic value of neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomized controlled trials.
    Liu S; Li H; Xue Y; Yang L
    PLoS One; 2023; 18(9):e0290888. PubMed ID: 37672511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment Strategy for Borderline Resectable Pancreatic Cancer With Radiographic Artery Involvement.
    Hirono S; Kawai M; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Ueno M; Yamaue H
    Pancreas; 2016 Nov; 45(10):1438-1446. PubMed ID: 27088490
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.
    Roland CL; Yang AD; Katz MH; Chatterjee D; Wang H; Lin H; Vauthey JN; Pisters PW; Varadhachary GR; Wolff RA; Crane CH; Lee JE; Fleming JB
    Ann Surg Oncol; 2015 Apr; 22(4):1168-75. PubMed ID: 25352267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant therapy with intensity-modulated radiotherapy combined with S-1 for borderline-resectable pancreatic cancer.
    Okamura Y; Nishitai R; Sasaki N; Ito H; Sakamoto T; Itokawa Y; Kusumoto M; Nakai Y; Yamaoka T; Manaka D
    Asia Pac J Clin Oncol; 2024 Aug; 20(4):546-554. PubMed ID: 38771310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials.
    Ghanem I; Lora D; Herradón N; de Velasco G; Carretero-González A; Jiménez-Varas MÁ; Vázquez de Parga P; Feliu J
    ESMO Open; 2022 Jun; 7(3):100485. PubMed ID: 35580504
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: A systematic review and meta-analysis of response and resection percentages.
    Tang K; Lu W; Qin W; Wu Y
    Pancreatology; 2016; 16(1):28-37. PubMed ID: 26687001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
    Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
    Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: A systematic review and meta-analysis.
    Lee YS; Lee JC; Yang SY; Kim J; Hwang JH
    Sci Rep; 2019 Oct; 9(1):15662. PubMed ID: 31666626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival benefit of neoadjuvant chemotherapy for resectable breast cancer: A meta-analysis.
    Chen Y; Shi XE; Tian JH; Yang XJ; Wang YF; Yang KH
    Medicine (Baltimore); 2018 May; 97(20):e10634. PubMed ID: 29768327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative efficacy and safety of neoadjuvant radiotherapy for patients with borderline resectable, and locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis protocol.
    Lv W; Wang Q; Hu Q; Wang X; Cao D
    BMJ Open; 2022 Jul; 12(7):e050558. PubMed ID: 35831044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic Value of Neoadjuvant Chemotherapy in Patients with Borderline Resectable Pancreatic Carcinoma Followed by Pancreatectomy with Portal Vein Resection and Reconstruction with Venous Allograft.
    Huang JC; Pan B; Wang HX; Chen Q; He Q; Lyu SC
    J Clin Med; 2022 Dec; 11(24):. PubMed ID: 36555996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of chemoradiotherapy and neoadjuvant chemoradiotherapy in resectable pancreatic cancer: a systematic review and meta-analysis.
    Xu CP; Xue XJ; Liang N; Xu DG; Liu FJ; Yu XS; Zhang JD
    J Cancer Res Clin Oncol; 2014 Apr; 140(4):549-59. PubMed ID: 24370686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
    Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N
    Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment.
    Takahashi S; Kinoshita T; Konishi M; Gotohda N; Kato Y; Kinoshita T; Kobayashi T; Mitsunaga S; Nakachi K; Ikeda M
    J Hepatobiliary Pancreat Sci; 2011 Jul; 18(4):567-74. PubMed ID: 21331805
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of neoadjuvant therapy and upfront surgery in resectable pancreatic cancer: a meta-analysis and systematic review.
    Ren X; Wei X; Ding Y; Qi F; Zhang Y; Hu X; Qin C; Li X
    Onco Targets Ther; 2019; 12():733-744. PubMed ID: 30774360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis.
    Ratnayake B; Savastyuk AY; Nayar M; Wilson CH; Windsor JA; Roberts K; French JJ; Pandanaboyana S
    J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32640720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant chemo-radiotherapy for patients with borderline resectable pancreatic cancer: a meta-analytical evaluation of prospective studies.
    Festa V; Andriulli A; Valvano MR; Uomo G; Perri F; Andriulli N; Corrao S; Koch M
    JOP; 2013 Nov; 14(6):618-25. PubMed ID: 24216547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elective nodal irradiation versus involved-field irradiation in patients with esophageal cancer receiving neoadjuvant chemoradiotherapy: a network meta-analysis.
    Liu T; Ding S; Dang J; Wang H; Chen J; Li G
    Radiat Oncol; 2019 Oct; 14(1):176. PubMed ID: 31619265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant S-1 with concurrent radiotherapy followed by surgery for borderline resectable pancreatic cancer: study protocol for an open-label, multicentre, prospective phase II trial (JASPAC05).
    Takahashi S; Ohno I; Ikeda M; Kobayashi T; Akimoto T; Kojima M; Konishi M; Uesaka K
    BMJ Open; 2017 Oct; 7(10):e018445. PubMed ID: 29061632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term outcome following neoadjuvant therapy for resectable and borderline resectable pancreatic cancer compared to upfront surgery: a meta-analysis of comparative studies by intention-to-treat analysis.
    Unno M; Hata T; Motoi F
    Surg Today; 2019 Apr; 49(4):295-299. PubMed ID: 30877550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.